CapWealth Advisors’s AstraZeneca AZN Stock Holding History

CapWealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-78	Closed	-$5K	–	106
2016 Q3	$5K	Buy	78 +28	+56%	+$1.83K	﹤0.01%	244
2016 Q2	$3K	Sell	50 -228	-82%	-$13.2K	﹤0.01%	251
2016 Q1	$16K	Buy	278 +228	+456%	+$13.7K	﹤0.01%	210
2015 Q4	$3K	Hold	50	–	–	﹤0.01%	240
2015 Q3	$3K	Hold	50	–	–	﹤0.01%	239
2015 Q2	$3K	Hold	50	–	–	﹤0.01%	256
2015 Q1	$3K	Buy	+50	New	+$3.47K	﹤0.01%	279
2014 Q4	–	Sell	-50	Closed	-$4K	–	105
2014 Q3	$4K	Hold	50	–	–	﹤0.01%	301
2014 Q2	$4K	Hold	50	–	–	﹤0.01%	300
2014 Q1	$3K	Hold	50	–	–	﹤0.01%	331
2013 Q4	$3K	Sell	50 -950	-95%	-$51.6K	﹤0.01%	335
2013 Q3	$52K	Hold	1,000	–	–	0.01%	143
2013 Q2	$47K	Buy	+1,000	New	+$50.9K	0.01%	152

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CapWealth Advisors's AZN Position: Q4 2016 in Review

CapWealth Advisors sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 78 shares — an estimated $5K sold.

CapWealth Advisors first reported a position in AZN in Q2 2013 and held it in 13 quarters. The position peaked at $52K in Q3 2013. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

CapWealth Advisors reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
CapWealth Advisors sold 78 AstraZeneca shares in Q4 2016, an estimated $5K.
CapWealth Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 13 quarters.
CapWealth Advisors's AstraZeneca position peaked at $52K in Q3 2013.
450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on CapWealth Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.